EYPT EyePoint, Inc.
Price Chart
Executive Summary
EyePoint, Inc. announced the first patient dosed in both Phase 3 COMO and CAPRI trials for DURAVYU (vorolanib intravitreal insert) in diabetic macular edema (DME), marking a key milestone in its clinical development. Topline data from these trials are expected in the second half of 2027, with DURAVYU positioned as a potential first-in-class TKI therapy for DME with sustained six-month dosing.
Actionable Insight
Monitor progress in Phase 3 trials and upcoming topline data in wet AMD (mid-2026) and DME (2H 2027) as key catalysts. Any safety issues or delays could negatively impact valuation, while positive data may drive upside.
Key Facts
- First patients dosed in Phase 3 COMO and CAPRI trials for DURAVYU in DME, a significant clinical milestone.
- DURAVYU is an investigational sustained-delivery TKI therapy targeting VEGF, PDGF, and IL-6 pathways in DME.
- Phase 3 trials are global, randomized, double-masked, and non-inferiority vs. aflibercept, enrolling ~240 patients each.
- Primary endpoint is non-inferiority in BCVA change at weeks 52 and 56; topline data expected in 2H 2027.
- DURAVYU is also in Phase 3 for wet AMD, with data expected beginning mid-2026.
- No safety signals observed in over 190 patients across four completed trials.
Financial Impact
No immediate financial impact; potential long-term commercial upside in multi-billion-dollar DME and wet AMD markets if approved.
Risk Factors
- Clinical trial results may not replicate Phase 2 success; interim data subject to change.
- Regulatory delays or failure to obtain FDA/EMA approval.
- Competition from existing and emerging anti-VEGF and sustained-release therapies.
- Cash runway uncertainty and potential need for future financing.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247217 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 14, 2026
26d ago
|
8-K
| $13.24 $12.78 | ▼ −3.47% | ▼ −2.76% | $11.77 (−11.10%) |
|
May 14, 2026
26d ago
|
Press Release
| $13.24 $12.78 | ▼ −3.47% | ▼ −2.76% | $11.77 (−11.10%) |
|
Apr 17, 2026
7w ago
|
144
| $15.07 $13.60 | ▼ −9.75% | ▼ −10.67% | $11.77 (−21.90%) |
|
Apr 13, 2026
8w ago
|
8-K
| $14.34 $14.11 | ▼ −1.60% | ▼ −3.00% | $11.77 (−17.92%) |
|
Mar 4, 2026
13w ago
|
Press Release
| $18.00 $14.92 | ▼ −17.11% | ▼ −15.78% | $11.77 (−34.61%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $18.34 $15.67 | ▼ −14.56% | ▼ −13.35% | $11.77 (−35.82%) |
|
Feb 28, 2026
14w ago
|
Institutional Cluster
| $18.34 $15.67 | ▼ −14.56% | ▼ −13.35% | $11.77 (−35.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access